文献リスト

1) Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285-8

2) Oshimi K. Progress in understanding and managing NK-cell malignancies. Br J Haematol. 2007; 139: 532-44

3) Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008; 26: 66-72

4) Chan JKC, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 204-7

5) Dijkman R, van Doorn R, Szuhai K, et al. Gene-expression profiling and array-based CGH classify CD4＋CD56＋ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007; 109: 1720-7

6) Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005; 81: 148-54

7) Au W, Intragumtornchai T, Nakamura S, et al. Clinical and pathological differences between nasal and nasal-Type NK/T cell lymphomas: A Summary of 136 cases from the International T Cell Lymphoma (ITCL) Project. Blood (ASH Annual Meeting Abstracts). 2006; 108: 292

8) Takahashi E, Asano N, Li C, et al. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology. 2008; 52: 585-96

9) Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T cell lymphoma of Waldeyer's ring. Blood. 2008; 112: 3057-64

10) Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008; 19: 1477-84

11) Cerroni L, Massone C, Kutzner H, et al. Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. Am J Surg Pathol. 2008; 32: 891-8

12) Xu JX, Hoshida Y, Yang WI, et al. Life-style and environmental factors in the development of nasal NK/T-cell lymphoma: a case-control study in East Asia. Int J Cancer. 2007; 120: 406-10

13) Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2007; 109: 2183-9

14) Ko YH, Park S, Jin H, et al. Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma. Lab Invest. 2007; 87: 241-50

15) Shim SJ, Yang W-I, Shin E, et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys. 2007; 67: 31-8

16) Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007; 18: 1382-7

17) Jeon YK, Park CH, Kim KY, et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol. 2007; 213: 170-9

18) Shen L, Au WY, Guo T, et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood. 2007; 110: 469-70

19) Kobayashi H, Nagato T, Takahara M, et al. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res. 2008; 68: 901-8

20) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-94

21) Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006; 24: 612-8

22) Na II, Kang HJ, Park YH, et al. Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol. 2007; 79: 1-7

23) Suwiwat S, Pradutkanchana J, Ishida T, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in the plasma of patients with peripheral T-cell and NK-cell lymphomas and peripheral T-cell proliferative diseases. J Clin Virol. 2007; 40: 277-83

24) Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for nasal NK/T-cell lymphoma. J Med Virol. 2007; 79: 562-72

25) Izutsu K, Yamaguchi M, Suzuki R, et al. Epstein-Barr virus DNA in peripheral blood and extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2008; 19: v153

26) Hsieh PP, Tung CL, Chan AB, et al. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am J Clin Pathol. 2007; 128: 579-84

27) Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-86

28) Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007; 18: 1685-90

29) Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007; 110: 652-9

30) Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008; 87: 613-21

31) Karantanis D, Subramaniam RM, Peller PJ, et al. The value of 18fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008; 8: 94-9

32) Yamaguchi M, Ogawa S, Nomoto Y, et al. Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop. 2001; 41: 93-9

33) Pagano L, Gallamini A, Trape G, et al. NK/T-cell lymphomas ‘nasal type': an Italian multicentric retrospective survey. Ann Oncol. 2006; 17: 794-800

34) Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma？ Ann Oncol. 2001; 12: 349-52

35) Lee SH, Ahn YC, Kim WS, et al. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica. 2006; 91: 427-8

36) Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995; 76: 2351-6

37) Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy＋/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2006; 47: 1274-82

38) Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000; 18: 54-63

39) Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24: 181-9

40) Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008; 70: 166-74

41) 小口正彦, 加賀美芳和, 今井 敦. 限局期NK/T細胞リンパ腫に対する放射線療法の意義と注意点. 血液フロンティア. 2006; 16: 1913-20

42) Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006; 106: 609-15

43) Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol. 2006; 79: 179-84

44) Yamaguchi M, Oguchi M, Tobinai K, et al. Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: results of a phase I portion of JCOG0211-DI. Blood (ASH Annual Meeting Abstracts). 2005; 106: 2685

45) Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant. 2006; 37: 819-824

46) Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008; 99: 1016-20

47) Kim BS, Kim DW, Im SA, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol. 2008 Aug 5. [Epub ahead of print]

48) Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005; 130: 561-7

49) Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006; 37: 425-31

50) Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol. 2008; 83: 721-7

51) Ito T, Makishima H, Nakazawa H, et al. Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur J Haematol. 2008; 81: 107-11

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp